External Resources

FDA-Approved Fixed-Duration CLL Therapies

• Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial - The Lancet Oncology
• Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | New England Journal of Medicine
• Fixed-Duration Venetoclax Plus Obinutuzumab as First-Line Treatment in Older Patients With CLL Who Have Comorbidities
• 1908 Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
• Venclexta for Previously Treated CLL/SLL
• Venclexta Prescribing Information
• Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
• Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
• Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
• Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen - PMC
• Chronic Lymphocytic Leukemia Treatment Algorithm 2022
• What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
• CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
• 330 Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

FDA-Approved Continuous-Duration CLL Therapies

• What are BTK Inhibitors for CLL?
• Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study
• Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
• Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
• ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | Journal of Clinical Oncology
• Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
• Next-Generation Targeted Therapy Zanubrutinib Found Superior to Ibrutinib for CLL and SLL - Hematology.org
• Brukinsa Patient Brochure
• Paper: Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
• Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
• What are BTK Inhibitors for CLL?

Side Effect Management of CLL Therapies

• Managing toxicities of Bruton tyrosine kinase inhibitors
• Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
• The Role of Mitochondrial Stress and the Late Sodium Current in Ibrutinib-Mediated Atrial Fibrillation
• Breyanzi Prescribing Information
• Cytokine release syndrome
• Grading of cytokine release syndrome associated with the CAR T cell therapy
• Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
• CAR T-Cell Grading and Management: ICANS
• In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
• Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
• Managing toxicities of Bruton tyrosine kinase inhibitors
• Ibrutinib-associated Arthralgias/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
• Venclexta
• Does Reducing My Ibrutinib Dose Impact My CLL Outcome?
• How Does Inflammation Influence CLL?
• Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
• Immunoglobulin Therapy or Antibiotics: Which is More Effective in Preventing CLL Patient Infections?
• Managing Fatigue, Anemia, and GI CLL Side Effects with Nutrition
• Cytopenia

Considerations for Treatment Selection

• Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
• Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
• Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
• Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
• Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study
• Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management
• Do CLL Patients Prefer Fixed-Duration or Continuous-Duration Therapy?

CLL Financial Resources 

• Medicare Prescription drugs (outpatient)
• What Medicare Part D drug plans cover
• Medicare Chemotherapy
• Drug Policy: Gazyva (obinutuzumab)
• CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
• CMS Oncology Care Model
• Drugs excluded from Part D coverage
• Parts of Medicare
• Inflation Reduction Act Research Series— Medicare Part D Enrollee Out-Of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
• Financial Considerations for CAR T-cell Therapy Patients
• Final CY 2026 Part D Redesign Program Instructions

The Future of CLL Treatment

• Precision diagnostics in chronic lymphocytic leukemia: Past, present and future
• Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
• Broadening the horizon: potential applications of CAR-T cells beyond current indications
• Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
• BTK inhibitors in CLL: second-generation drugs and beyond
• Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
• Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning
• Racial and Socioeconomic Disparities Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in the US Community Oncology Setting